Draft monograph: Thymosin beta-4 — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Every contributing trial shares one sponsor and the monograph does not say so — arising from DRAFT-THYMOSIN-BET/001. Sponsor concentration is now stated with the certainty rating, and the monograph records how many independent sponsors contributed evidence to each assessed outcome.
2. Doses are expressed in units that differ between sections — arising from DRAFT-THYMOSIN-BET/002. A single dose unit is now used throughout each monograph, with the source unit retained in parentheses wherever a conversion was applied, and every conversion is stated rather than performed silently.
3. The certainty rating for the principal assessed outcome cannot be traced to the contributing trials — arising from DRAFT-THYMOSIN-BET/003. Each assessed outcome now carries its downgrade domains in the summary-of-findings row, with a short statement of the judgement made in each, so that the rating can be checked domain by domain against the contributing trials.
4. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-THYMOSIN-BET/004. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
5. Regulatory status is stated without naming the jurisdiction — arising from DRAFT-THYMOSIN-BET/005. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
6. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-THYMOSIN-BET/006. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
7. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-THYMOSIN-BET/007. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
8. References should carry a persistent identifier for every cited source — arising from DRAFT-THYMOSIN-BET/008. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
9. Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as… — arising from DRAFT-THYMOSIN-BET/009. Mechanistic claims not traceable to a primary source are removed, and those retained carry their source and a statement of whether the underlying work was conducted in vitro, in animals or in humans.
10. The supply section does not record that endotoxin is not determined — arising from DRAFT-THYMOSIN-BET/010. Section 8 now carries an explicit endotoxin line for every compound supplied in an injectable presentation, and states plainly that an undetermined attribute is undetermined rather than acceptable.
11. Two factual descriptions of the sponsor's programme are inaccurate — arising from DRAFT-THYMOSIN-BET/011. The trial status now reads as completed at a pre-specified interim analysis, with the analysis identified, and the dose is stated in the unit used in the approved labelling. The submission is identified as an industry submission on its face in accordance with…
12. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-THYMOSIN-BET/012. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
13. Nothing is said about impaired renal or hepatic clearance — arising from DRAFT-THYMOSIN-BET/013. The pharmacokinetic table now carries renal and hepatic rows in every monograph, populated with the study where one exists and with an explicit statement of absence where none does.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.